Is Exemestane More Effective Than Tamoxifen in Reducing Recurrence After Early-Stage Breast Cancer Treatment?

According to a recently published study in the British medical journal “New England Journal of Medicine,” exemestane was more effective than tamoxifen in preventing recurrence after early-stage breast cancer treatment.
Breast cancer is the most common cancer in women. Lifetime risk is approximately %12, meaning one in every 8 women will develop it. Prevention and early diagnosis are priorities, but effective treatment and prevention of recurrence are equally important. Disease returning when a patient believes she has recovered is devastating for her and her family. Surgery to remove the tumor is currently commonly used for early-stage cancer, followed by recurrence-prevention strategies.
In early-stage hormone receptor-positive breast cancer, ovarian suppression to reduce the estrogen source and additional protective treatment (adjuvant therapy) with tamoxifen prevent recurrence. ‘Hormone receptor-positive’ means cancer cells are estrogen-sensitive and estrogen contributes to development. Suppressing it is therefore effective. Tamoxifen is conventionally used to prevent recurrence after treatment, but a recently published comprehensive study found exemestane more effective.
Among approximately 4700 premenopausal women with early-stage breast cancer, around 2350 received exemestane and 2350 tamoxifen. Both groups also received ovarian-suppressing medication to prevent unwanted effects and were followed for 68 months. Analysis found more disease-free patients, fewer recurrences and higher 5-year survival with exemestane. Bone and joint pain, vaginal dryness and reduced sexual desire were more frequent with exemestane; hot flashes and vaginal discharge were more frequent with tamoxifen. Overall quality of life did not differ substantially.
In conclusion, adjuvant exemestane is progressing toward becoming a new, effective option for preventing recurrence in premenopausal women with early-stage hormone receptor-positive breast cancer. More studies are nevertheless needed before it becomes standard treatment.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.